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Abstract
Background: Studies have shown that the VP22 gene of Marek’s Disease Virus type-1 (MDV-1) has the property of
movement between cells from the original cell of expression into the neighboring cells. The ability to facilitate the
spreading of the linked proteins was used to improve the potency of the constructed DNA vaccines against
chicken anemia virus (CAV).
Methods: The VP1 and VP2 genes of CAV isolate SMSC-1 were amplified and inserted into eukaryotic co-
expression vector, pBudCE4.1 to construct pBudVP2-VP1. We also constructed pBudVP2-VP1/VP22 encoding CAV
VP2 and the VP22 of MDV-1 linked to the CAV VP1. In vitro expression of the genes was confirmed by using RT-
PCR, Western blot and indirect immunofluorescence. The vaccines were then tested in 2-week-old SPF chickens
which were inoculated with the DNA plasmid constructs by the intramuscular route. After in vivo expression
studies, immune responses of the immunized chickens were evaluated pre- and post-immunization.
Results: Chickens vaccinated with pBudVP2-VP1/VP22 exhibited a significant increase in antibody titers to CAV and
also proliferation induction of splenocytes in comparison to the chickens vaccinated with pBudVP2-VP1.
Furthermore, the pBudVP2-VP1/VP22-vaccinated group showed higher level of the Th1 cytokines IL-2 and IFN-g.
Conclusions: This study showed that MDV-1 VP22 gene is capable of enhancing the potency of DNA vaccine
against CAV when fused with the CAV VP1 gene.
Background
Chicken anemia virus (CAV) is a small non-enveloped
virus of genus Gyrovirus from Circoviridae family, which
causes anemia in young susceptible chickens and subcli-
nical infections in older chickens [1-3]. Commercially
available vaccines against CAV infection which are
based on non-attenuated virulent CAV propagated in
chicken embryos [4] or attenuated live vaccine [5] can-
not be used in chickens in lay and within 21 days of
slaughter. Furthermore, live attenuated vaccine may
cause clinical disease if not attenuated sufficiently and
sometimes spreading of the modified viruses to young
chickens may cause the disease. In a recent develop-
ment, plasmid DNA-based vaccines have emerged as
one of the more promising applications of non-viral
gene therapy. One such subunit vaccine against infec-
tious chicken anemia was developed by using recombi-
nant baculovirus as a vector for the expression of the
CAV proteins [6]. They found that co-synthesis of VP1
and VP2 is required for the induction of neutralizing
antibodies.
A limitation in the use of DNA vaccine is its inability
to spread in vivo. Thus, a strategy to facilitate the spread
of the antigen may significantly enhance the potency of
the vaccine. This can be demonstrated by the fusion of
the VP22 gene of Marek’s disease virus type-1 (MDV-1)
to the target gene encoding the antigenic protein. It has
been shown that the VP22 protein of Marek’sd i s e a s e
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DNA vaccine potency by facilitating intercellular spread-
ing of the linked protein [7]. The MDV-1 VP22 is a
phosphorylated protein with a DNA-binding activity
located at the N terminus of the protein that displays
cell trafficking properties [8]. In fact, VP22 is a tegu-
ment protein involved in intercellular transport and
movement between cells from the original cell of
expression into the neighboring cells [9,10].
We therefore investigated the use of MDV-1 VP22
linked to CAV VP1 gene in a recombinant DNA plas-
mid, namely pBudVP2-VP1/VP22 which allows the
CAV VP1 fused to MDV-1 VP22 to be simultaneously
expressed with the CAV VP2.
Material and methods
Expression vector and viral genes
The pBudCE4.1 co-expression vector (Invitrogen, USA)
was used to construct the DNA vaccines. The vector
contains the human cytomegalovirus (CMV) immediate-
early promoter and the human elongation factor 1a-
subunit (EF-1a) promoter for high-level, constitutive,
independent expression of two recombinant proteins.
T h eV P 2 2g e n eo fM D V - 1s t r a i nC V I 9 8 8 / R i s p e n s
(Accession No: AY311498) and recombinant pCRVP1-
VP2 cloning vector containing VP1 and VP2 genes of
CAV isolate SMSC-1 (Accession No. AF285882) were
obtained from the Faculty of Veterinary Medicine, Uni-
versity Putra Malaysia (UPM).
Construction of DNA vaccines
In this study, two DNA plasmids, namely pBudVP2-VP1
and pBudVP2-VP1/VP22 were constructed. The VP1
and VP2 genes of CAV were amplified from the recom-
binant plasmid PCRVP1-VP2 using specific primers for
the CAV VP1 and VP2 genes listed in Table 1. Reverse
primers were designed without stop codon to insert the
genes upstream of the His-tag sequence. The VP1 gene
was inserted into the NotIa n dKpnI cloning sites of
pBudCE4.1 plasmid under the control of the EF-1a pro-
moter. The VP2 gene of CAV was then inserted into
the SalIa n dBamHI sites of CMV promoter in the
pBudVP1 construct to generate pBudVP2-VP1. To con-
struct the pBudVP2-VP1/VP22, the MDV-1 VP22 DNA
fragment was amplified using a set of primers listed in
Table 1 and then cloned into the KpnI and XhoI cloning
sites of pBudVP2-VP1 in the frame with the VP1 gene.
After DNA transformation into Escherichi coli Top10,
the inserted genes were verified by restriction-enzyme
analysis and PCR. The identical sequence of the inserts
was confirmed by double-stranded sequencing. All the
plasmid constructs and the control plasmid were puri-
fied using a large-scale Endotoxin-free plasmid purifica-
tion kit (Endo-free Maxiprep Kit, Qiagen, USA).
In vitro transcription and translation of the constructs
In vitro expression of the recombinant plasmids was car-
ried out in chicken MDCC-MSB1 cell line. The MSB1
cells were transfected with the plasmids using Lipofecta-
mine™2000 reagent (Invitrogen, USA) according to the
manufacturer’s recommendation with some modifica-
tions. After 48 h of transfection, expression of the genes
was evaluated by RT-PCR, Western blot and indirect
immunofluorescence.
Total RNA was extracted from the transfected MSB1
cells using Trizol and then treated with DNase I to
remove DNA contamination. To confirm DNA removal
from the samples, they were tested by PCR using speci-
fic primers for the inserted genes. The RNA from nor-
m a lM S B 1c e l l sw a su s e da sn e g a t i v ec o n t r o l .R T - P C R
Table 1 Primers for (A): PCR amplification and RT-PCR analysis of the viral genes; (B): RT-PCR analysis of chicken
cytokines
Gene Accession Number Sequence (5’ to 3’) Expected product size (base pair)
A:
CAV VP1 AF285882 Forward
Reverse
CTAACGCGGCCGCACCATGGCAAGACGAGCTCGC
CTAGGGGTACCCCAGTACATGGTGCTGTTGG
1335
CAV VP2 AF285882 Forward
Reverse
GCTAAGTCGACACCATGCACGGGAACGGC
CATGGGGATCCCACTATACGTACCGGGGC
648
MDV-1 VP22 AY311498 Forward
Reverse
CATGGGGTACCATGGGGGATTCTGAAAGGC
GTACGCTCGAGTCGCTATCACTGCTACGAT
728
B:
IL-4 NM_001007079 Forward
Reverse
AGCTCTCAGTGCCGCTGATG TAGCTAGTTGGTGGAAGAAGG 321
IL-6 NM_204628 Forward
Reverse
ATGAACTTCACCGAGGGCTGC ACGGTCTTCTCCATAAACGAAG 680
IL-12 AY262752 Forward
Reverse
ACACATCTGATGAAGCACTGCC
TTGGGATATGTCCAGGTC-ACAG
598
b-actin
(positive control)
EU931581 Forward
Reverse
ATGTGCAAGGCCGGTTTCGC
TCCTCAGGGGCTACTCTCAG
254
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Thermal Cycler (BioRad, USA). Following a reverse
transcription step at 45°C for 45 min, the samples were
denatured at 94°C for 3 min and amplification was car-
ried out in 35 cycles 94°C for 40 s, 55°C for 1 min and
68°C for 2 min; and a final elongation step at 68°C for
10 min. RT-PCR products were then analyzed by elec-
trophoresis on a 1% agarose gel.
In vitro translation of the genes was studied by
Western blotting using chicken anti-CAV serum and
mouse anti-His monoclonal antibody (Promega, USA) as
primary antibodies. Expression of the genes was also
evaluated by immunofluorescence test according to
Richter and Wick [11] using chicken anti-CAV serum as
primary antibody and fluorescein isothiocyanate (FITC)-
conjugated anti-chicken IgY (Promega, USA) as
secondary.
Evaluation of DNA vaccines in SPF chickens
Specific pathogen free (SPF) chicken eggs taken from
Malaysian Vaccines & Pharmaceuticals Sdn Bhd,
Malaysia were hatched and maintained under specific-
pathogen free condition with free access to feed and
water. Two-week-old SPF chickens (n = 10) were vac-
cinated with 150 μg of pBudVP2-VP1, pBudVP2-VP1/
VP22, parental plasmid or 1x PBS via intramuscularly
injection. Chickens were boosted two times with the
same regimen as the first injection, at 2 weeks inter-
vals. Blood was withdrawn from the wing vein of the
chickens before and 10 days after the last injection and
collected sera were kept in -20°C for further analysis.
All procedures were conducted with the protocols
approved by Animal Care and Use Committee of the
Faculty of Veterinary Medicine, University Putra
Malaysia (UPM).
In vivo expression analysis
Transcriptional expression of VP1, VP2 and MDV-1
VP22 genes was determined in the vaccinated groups by
RT-PCR using the specific primers. Ten days after the
last vaccination, the chickens were sacrificed and their
skeletal muscle (at the site of injection) was harvested;
homogenized and their total RNA was extracted. After
treatment with DNase I, DNA removal was confirmed
by PCR and then DNA-free samples were subjected to
RT-PCR as described above.
Western blotting was also used to show in vivo
expression of the proteins, where a section of the har-
vested muscles at the site of injection was homogenized
and then treated with RIPA (50 mM Tris pH 7.4, 150
mM NaCl, 1 mM EDTA, 5 μg/ml Aprotinin, 5 μg/ml
Leupeptin, 1% Triton X-100, 1% Sodium deoxycholate,
0.1% SDS) containing 1 mM protease inhibitor PMSF
(phenylmethylsulfonyl fluoride). The extracted proteins
were mixed with 2× sample buffer (1.25 ml Tris-HCl,
pH 6.8, 20% glycerol, 4% SDS, 0.02% (w/v) bromophenol
blue, 10% 2-mercaptoethanol) followed by 5-10 min
boiling at 95°C. The protein mixtures were subjected to
Western blot analysis using primary chicken anti-CAV
serum and secondary goat anti-chicken IgY conjugated
to alkaline phosphatase.
Antibody titer to CAV
Serum antibody titers against CAV were determined,
pre- and post-vaccination, using IDEXX ELISA kit
(IDEXX, Portland, ME, USA). The kit uses an anti-CAV
monoclonal antibody in a blocking format ELISA for
the detection of antibodies to CAV in chicken serum.
Briefly, Samples were diluted at 1:100 dilutions and then
added into microtiter wells coated with CAV antigen
followed by 60 min incubation at RT. After 3 times
washing with washing buffer, anti-CAV monoclonal
antibody conjugated with horseradish peroxidase was
added and then incubated at RT for 30 min. Following
the incubation period, the unreacted anti-CAV conju-
gate was removed by 3 times washing and TMB sub-
strate solution (100 μl) was then added into the wells
followed by 15 min incubation at RT. The reaction was
stopped by adding 100 μl of the stop solution and the
absorbance value was measured at 650 nm. All sample
ODs were normalized to the negative control (S/N =
sample OD650/negative control OD650). The antibody
titers were calculated based as the following calculation,
log10 titer = (S/N-2.72)/-0.64. ELISA titers higher than
1000 were considered as positive.
Neutralizing antibody titer
To investigate whether the produced antibodies have
virus neutralization activity, the collected sera were ana-
lyzed for neutralization antibody titer against CAV
infection in chicken MSB1 cells. The assay was carried
out by the measurement of cell proliferation and viabi-
lity using WST-1 reagent (Roche, Germany) as
described by Moeini et al. [12] and Lehtoranta et al.
[13].
Cytokines production assay
The serum level of Th1 cytokines, interleukin 2 (IL-2)
and interferon g (IFN-g) was determined by ELISA kits
(Cusabio Biotech, USA). Thep r o c e d u r ew a sf o l l o w i n g
the procedure recommended by the manufacturer. For
the reason that no commercial ELISA kits were available
for the detection of chicken IL-12, IL-4 and IL-6 which
have important roles in the differentiation of CD4
+ T
cells into Th1 or Th2 cells, transcriptional expression of
these cytokines were studied in the spleen of the immu-
nized chickens by RT-PCR using the specific primers
listed in Table 1.
Moeini et al. Virology Journal 2011, 8:119
http://www.virologyj.com/content/8/1/119
Page 3 of 9Splenocyte proliferation assay
The proliferation response of the chicken splenocytes to
the CAV VP1 protein was studied after immunization.
The VP1 protein of CAV was prepared and purified from
a recombinant E. coli BL21 (DE3) expressing the VP1 and
VP2 genes of CAV, synchronously (data not shown). At
10 days of immunization, single cell suspensions were gen-
erated from the harvested spleens in PBS-EDTA solution
(1X PBS, pH 7.4, 2 mg/ml EDTA) supplemented with 2%
penicillin/streptomycin. Red blood cells were removed by
washing the cell suspensions with red blood cell lysis solu-
tion containing 0.84% NH4CL, 0.1% NaHCO3 and 1.8 ml
of 5% EDTA. The splenocytes were pelleted at 1000 rpm
for 10 min and then resuspended in DMEM medium sup-
plemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. Viable splenocytes were added to 96-well
plates in 0.1 ml at 2 × 10
4 cells/well and incubated in tri-
plicate with CAV antigen (purified VP1 protein), mitogen
phytohemagglutinin (PHA, Sigma) as positive control, or
medium alone as negative control followed by 3 days incu-
bation at 37°C in an atmosphere of 5% CO2. The prolifera-
tion response was evaluated by BrdU cell proliferation
assay kit (Exalpha Biologicals, USA). Data was reported as
stimulation indices (SI), which was the mean of experi-
mental wells/mean of antigen free wells (negative control).
Statistical Analysis
The data was analyzed by t-test and statistical signifi-
cance was set at P < 0.05. The results were expressed as
means ± standard error of mean. All the analysis was
carried out using GraphPad Prism 5 and Windows
Microsoft Excel 2007.
Results
Construction of plasmids
The VP1 and VP2 genes of CAV isolate SMSC-1 were
amplified and cloned into the vector pBudCE4.1 to
construct pBudVP2-VP1 encoding VP1 and VP2, syn-
chronously. The pBudVP2-VP1/VP22 DNA plasmid was
also constructed by insertion of the VP22 gene of
MDV-1 into pBudVP2-VP1 in the frame with VP1. The
plasmid constructs had the correct orientation and the
correct order of the reading frames (data not shown).
The final constructs are shown in Figure 1.
In vitro characterization of the constructs
In vitro expression of the DNA plasmids was carried out
in chicken MSB1 cells. RT-PCR analysis of the DNA-free
RNAs using the respective primers for VP1, VP2 and
VP22 revealed the presence of the mRNA of the genes in
the transfected cells indicating the successful in vitro tran-
scriptional expression of the constructs (Figure 2A & 2B).
In vitro translation of the DNA vaccines was con-
firmed by Western blot analysis of the transfected
MSB1 cells (Figure 2C). The expression of VP1 (~56
KDa) and VP1/VP22 (~82 KDa) proteins were detected
in the cells transfected with pBudVP2-VP1 or pBudVP2-
VP1/VP22, respectively using both anti-His and anti-
CAV primary antibodies. The VP2 protein (~27 KDa)
was detected in the both transfected cells using anti-His
monoclonal antibody (Figure 2C, lanes 4 and 5).
Indirect immunofluorescence using chicken anti-CAV
serum followed by FITC-conjugated anti-chicken IgY also
revealed the expression of the encoded proteins. Cells
transfected with pBudVP2-VP1 or pBudVP2-VP1/VP22
exhibited bright cytoplasmic fluorescence (Figure 3A &
3B) compared with the cells transfected with the parental
plasmid that showed no fluorescence (Figure 3C) indicat-
ing that the VP1 protein linked to the MDV-1 VP22 gene
capable to recognize and interact with anti-CAV antibody.
In vivo evaluation of the DNA vaccines
The DNA plasmids were tested in SPF chickens via
intramuscularly injection. Chicken were boosted twice,
Figure 1 Map of pBudVP2-VP1 and pBudVP2-VP1/VP22. pBudVP2-VP1 was constructed by cloning of the CAV VP1 gene into the NotIa n d
KpnI of EF-1a MCS and VP2 gene into the SalI and BamHI sites of CMV MCS of pBudCE4.1. To generate pBudVP2-VP1/VP22, the MDV-1 VP22
DNA fragment was inserted into the KpnI and XhoI cloning sites of the constructed pBudVP2-VP1 plasmid in the frame with the CAV VP1 gene.
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RT-PCR revealed the transcriptional expression of VP1,
VP2 and MDV-1 VP22 in the skeletal muscle at the site
of injection (Figure 4A & 4B). Furthermore, Western
blot analysis showed the expression of VP1 and VP1/
VP22 proteins at the site of injection in the chickens
vaccinated with pBudVP2-VP1 or pBudVP2-VP1/VP22,
respectively (Figure 4C).
Serum antibody titer and VN titer to CAV in the
vaccinated chickens
Serum antibody titer to CAV was determined in the
chickens pre- and post-vaccination by ELISA. As shown
in Figure 5 vaccinated Chickens with pBudVP2-VP1/
VP22 showed a significant increase (P < 0.05) in anti-
body titer (2700 ± 100) compared with the pBudVP2-
VP1-vaccinated chickens (1853 ± 89). No detectable
response was detected in the control groups injected
with PBS or the parental plasmid.
To investigate the neutralization activity of the serum
antibodies, virus neutralization test was carried out in
MSB1 cells. According to the results summarized in
Table 2 both groups showed positive virus neutralization
activity with titer ranging from 1:256 to 1:512. From
eight pBudVP2-VP1/VP22-injected samples, 6 samples
h a dV Nt i t e ro f1 : 5 1 2 ,w h i l eo n l yo n eo ft h es e v e n
pBudVP2-VP1-injected samples showed VN titer of
1:512.
Cell-mediated responses after DNA vaccination
Cell-mediated immunity was evaluated in the vaccinated
group through cytokines evaluation and in vitro prolifera-
tion assay of splenocytes pre- and post-immunization.
Splenocytes of the immunized chickens were stimulated
with the antigenic VP1 protein, or PHA as positive con-
trol. The assay showed positive proliferation response in
the both vaccinated groups, although the VP1-induction
level in the pBudVP2-VP1/VP22-immunized group was
significantly higher (mean SI 11.12) compared to the
pBudVP2-VP1 group (mean SI 7.63) (Figure 6). The con-
trols inoculated with parental plasmid showed negative
responses (SI < 2) to the CAV VP1 protein.
To explore whether the DNA vaccines lead to the
induction of Th1 or Th2 response, serum levels of Th1
Figure 2 In vitro expression analysis of the constructs in chicken MSB1 cells by RT-PCR (A and B) and Western blotting (C). (A) RT-PCR
results for VP1 and VP2 (lanes 1 and 2, respectively) in the pBudVP2-VP1-transfected cells. (B) RT-PCR results for VP1, VP2 and VP22 (lanes 1-3) in
the pBudVP2-VP1/VP22-transftected cells; M: GeneRuler™DNA Ladder Mix (Fermentas, Canada). (C) Western blotting results by using chicken
anti-CAV (lanes 1-3) or anti-His (lanes 4 and 5) in the cells transfected with pBudVP2-VP1/VP22 (lane 1 and 5), pBudVP2-VP1 (lane 2 and 4) or in
non-transfected cells (lane 3).
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Page 5 of 9Figure 3 Indirect immunofluorescence analysis. MSB1 cells were transfected with the recombinant plasmids by using Lipofectamine 2000
reagent and 2 days after transfection, transient expression of the encoded proteins was explored by indirect immunofluorescence using primary
anti-CAV polyclonal antibody. (A) Cells transfected with pBudVP2-VP1; (B) Cells transfected with pBudVP2-VP1/VP22; and (C) Cells transfected with
the parental plasmid.
Figure 4 In vivo expression analysis of the viral genes in the injected chickens by RT-PCR (A & B) and Western blotting (C). (A) RT-PCR
results for the chicken injected with pBudVP2-VP1. (B) RT-PCR results for the chicken injected with pBudVP2-VP1/VP22; M: GeneRuler™DNA
Ladder Mix (Fermentas, Canada). (C) Western blotting results in the chicken injected with pBudVP2-VP1/VP22 (lane 1), pBudVP2-VP1 (lane 2) or
parental plasmid (lane 3).
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No significant differences were observed between the
pBudVP2-VP1- and pBudVP2-VP1/VP22-vaccinated
groups and controls pre-immunization, while the serum
level of IL-2 and IFN-g was significantly (P < 0.05)
higher in the vaccinated groups post-vaccination when
compared to the control group (Figure 7). However,
compared with the pBudVP2-VP1 group, the pBudVP2-
VP1/VP22 group showed higher levels of IL-2 and IFN-
g (P < 0.05). Furthermore, transcriptional expression
analysis showed the presence of IL-12 mRNA in the
vaccinated groups, whereas the mRNA of IL-4 and IL-6
was not detected (results not shown).
Discussion
According to the previous studies [6,14,15] and the find-
ing of our group [12], co-synthesis of the VP1 and VP2
proteins is required to produce the essential neutralizing
form of VP1 resulting in the efficient induction of anti-
body response to CAV, whereas separate expression of
VP1 does not. In fact, VP2 may play a role as a scaffold
protein during virion assembly, but is removed in the
next step [14,15]. Therefore, pBudVP2-VP1 plasmid co-
expressing the VP1 and VP2 genes of CAV was devel-
oped as a DNA vaccine against CAV. To explore
whether the linkage of MDV-1 VP22, as a tegument
protein with a property of intercellular transport, to
CAV VP1 protein lead to enhance the potency of the
DNA vaccine, the pBudVP2-VP1/VP22 plasmid encod-
ing the fusion protein VP1/VP22 and VP2 protein was
also constructed.
In vitro analysis of the constructs revealed the success-
ful transcriptional and translational expression of the
genes in MSB1 cells. In agreement with the immuno-
blotting results, immunofluorescence staining of the
transfected cells showed the reaction of the VP1 and the
fusion protein, VP1/VP22 with anti-CAV polyclonal
antibody resulting in bright cytoplasmic fluorescence.
These observations indicated that the VP1 protein has
proper secondary folding to induce immune system to
CAV. The plasmid constructs were then tested in SPF
chickens. In vivo expression analysis matched up well
Figure 5 Antibody responses to CAV as determined by ELISA pre- and post-vaccination. Control groups were inoculated with PBS and
pBudCE4.1 plasmid. Antibody titers higher than 1000 were considered positive. The error bars indicate the standard errors of the means.
Table 2 Neutralization activities of the serum antibodies in the vaccinated groups
Virus neutralization test
Sera groups No. of samples No. of positive VN antibody titer VN status
pBudVP2-VP1/VP22 8 2 1:256 positive
pBudVP2-VP1 7 6 1:512 positive
parental plasmid 2 6 1:256 positive
PBS 2 1 1:512 positive
- 0 Negative
- 0 Negative
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t r a n s l a t i o ne x p r e s s i o no ft h eg e n e si nt h ei m m u n i z e d
chickens.
To investigate the ability of the linkage MDV-1 VP22
to CAV VP1 to enhance the potency of the DNA vac-
cine, immune responses were evaluated in the chickens
vaccinated with the plasmid encoding VP1/VP22 and
the results were compared with those from the chickens
vaccinated with pBudVP2-VP1. Antibody titer to CAV
was significantly higher (P < 0.05) in the group vacci-
nated with pBudVP2-VP1/VP22 in comparison with the
group vaccinated with pBudVP1-VP2. Virus neutraliza-
tion (VN) test indicated positive neutralization activity
of the antibodies in the both vaccinated groups with
moderate protective titer ranging from 1:256 to 1:512.
However, the number of samples with VN titer of 1:512
was obviously higher in the pBudVP2-VP1/VP22-vacci-
nated group. Similarly such presence of neutralizing
antibodies against CAV has been shown to provide pro-
tection against CAV in young chickens [16-21]. Never-
theless, in order to confirm this issue, it is suggested
that breeder flocks producing day-old chicks with
maternal antibodies be vaccinated for virus challenge.
Cytokine assay by ELISA showed high level of IL-2
and IFN-g in the both vaccinated groups post-immuni-
zation, although their levels were higher in the
pBudVP2-VP1/VP22 group. Furthermore, the expression
of IL-12 which triggers the differentiation of Th1 [22]
was detected by RT-PCR in the spleen of the both
groups, whereas IL-4 and IL-6 which are involved in dif-
ferentiation of Th2 [22,23] were not detected in any
samples. These observations indicate a pattern of cyto-
kine production that most closely promotes the Th1
T-helper cell responses which are known to be involved
in cellular-mediated immunity [22,24].
To further investigation whether the linkage of
MDV-1 VP22 lead to enhance antigen-specific immune
responses, we compared antigen-stimulated proliferative
response in the splenocytes of the vaccinated groups.
Compared to the pBudVP2-VP1-vaccinated group, the
pBudVP2-VP1/VP22-vaccinated group exhibited a sig-
nificant increase in the proliferation induction of spleno-
cytes indicating higher VP1-specific immune responses
in the presence of the MDV-1 VP22 protein.
Conclusions
The results of the present study showed that the fusion
of the MDV-1 VP22 to the target gene, CAV VP1,
could significantly increase CAV-specific immune
responses. This view is supported by Hung et al. [7],
who showed the capacity of the VP22 protein of Marek’s
disease virus type-1 (MDV-1) to improve DNA vaccine
potency by facilitating intercellular spreading of the
linked protein.
Figure 6 Proliferative induction of splenocytes from the
immunized chickens. Ten days after the last injection, proliferation
response was evaluated by BrdU cell proliferation assay kit as
described in material and methods. Cell induced with mitogen
phytohemagglutinin (PHA) were used as positive control. Data was
reported as stimulation indices (SI). SI greater than two was
considered positive.
Figure 7 Serum level of IL-2 and IFN-g in the vaccinated
chickens. The serum levels of Th1 cytokines, IL-2 (A) and IFN-g (B)
were determined in pBudVP2VP1-, pBudVP2-VP1/VP22- and the
control group. The results showed higher levels of IL-2 and IFN-g in
the immunized groups compared to those from the control group.
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